Trazodone and Cognitive Function: What the Evidence Actually Shows

What the label says about thinking

The label carries a specific warning headed Potential for Cognitive and Motor Impairment: trazodone has the potential to impair judgment, thinking and motor skills, and patients are advised to use caution when operating machinery [1]. The same item is listed among the drug's serious adverse reactions [1]. The only approved indication is major depressive disorder in adults; there is no insomnia indication and no insomnia dose, so sleep use is off-label [1].

The label describes trazodone as a selective serotonin reuptake inhibitor and a 5-HT2 receptor antagonist, a triazolopyridine derivative, and it notes alpha-1 adrenergic blockade, which the label links to postural hypotension [1]. Preclinical binding values given in the label are 367 nM at the serotonin transporter and 35.6 nM at 5-HT2A [1].

What the controlled trials recorded

Table 2 of the label reports adverse reactions from controlled MDD studies. In outpatients (157 on trazodone, 158 on placebo), drowsiness was reported by 41% versus 20%, dizziness or lightheadedness by 28% versus 15%, blurred vision by 15% versus 4%, headache by 20% versus 16% and fatigue by 6% versus 3% [1]. Decreased concentration was reported by 1% versus 0%, and confusion by 6% versus 8% [1]. Impaired memory sits in the label's separate list of reactions reported in under 2% of patients during controlled studies, alongside impaired speech and hallucinations or delusions [1].

The inpatient studies (142 on trazodone, 95 on placebo) recorded higher rates of nervous-system effects: drowsiness 24% versus 6%, confusion 5% versus 0%, disorientation 2% versus 0% and incoordination 5% versus 0% [1]. These are counts of reported side effects, not scores on cognitive tests, and the label cautions that adverse-reaction rates from trials of different drugs cannot be directly compared [1].

Has performance been measured directly?

The clearest performance testing came from a drug-interaction study rather than a dedicated cognition study. A blinded four-way crossover gave 10 healthy volunteers single 50 mg doses of trazodone with low-dose ritonavir or with placebo [3]. Ritonavir cut trazodone's apparent oral clearance from 155 to 75 mL/min, lengthened elimination half-life from 6.7 to 14.9 hours and raised peak levels from 842 to 1,125 ng/mL [3]. Volunteers had more sedation, fatigue and performance impairment, and the only test that separated the two conditions was the digit-symbol substitution test; three of the ten had nausea, dizziness or hypotension and one also fainted [3].

What the wider sleep literature shows

A 2005 review of trazodone for insomnia identified 18 studies [4]. The review concluded that evidence for efficacy in insomnia was very limited, that most studies were small, conducted in depressed patients, had design problems and often lacked objective measures, and that side effects were not inconsequential, with a high incidence of discontinuation for sedation, dizziness and psychomotor impairment and particular concern about use in the elderly [4]. It also noted some evidence of tolerance [4]. A 2005 systematic review of antidepressants and sleep lists trazodone among the sedating antidepressants and reports REM sleep suppression with it [5].

How long trazodone stays in the body

The label itself does not give a half-life [1]. Measured values vary with the person. In 8 healthy volunteers given 100 mg orally, terminal half-life was 7.3 +/- 0.8 hours and bioavailability about 63 to 65%, and food lowered the peak level from 1.88 to 1.47 micrograms/mL and delayed it from 1.3 to 2.0 hours without changing total absorption [2]. In a study of healthy young (18 to 40 years) and elderly (60 to 76 years) subjects, half-life was 8.2 hours in elderly men versus 4.7 hours in young men, and 7.6 versus 5.9 hours in women [6]. In 23 obese subjects it was 13.3 hours versus 5.9 hours in 23 matched normal-weight controls [6].

When blood levels rise

Trazodone is a CYP3A4 substrate, and CYP3A4 forms its active metabolite, m-chlorophenylpiperazine [1][7]. A 2025 in vitro study found that CYP2D6, CYP2C19 and flavin monooxygenases contribute to other, inactive metabolites, while CYP3A4 remains the primary enzyme [8]. The label says that strong CYP3A4 inhibitors increase trazodone exposure and the risk of adverse reactions including arrhythmias, and that a lower dose should be considered based on tolerability; strong inducers lower exposure and may call for a higher dose [1]. The label also warns that trazodone may enhance the effects of alcohol, barbiturates and other central nervous system depressants, and that overdose deaths have occurred when it was taken with alcohol or other depressants [1].

Older adults

The label reports orthostatic hypotension and syncope, and in MDD outpatients the rates were hypotension 4% versus 0% and syncope 5% versus 1% [1]. It also lists hyponatremia and SIADH, with higher risk in older adults [1]. Half-life is longer in elderly men than young men in the pharmacokinetic data described above [6], and the 2005 review singled out sedation, dizziness and psychomotor impairment as a particular concern in elderly patients [4].

Might trazodone protect against dementia?

The relevant findings are preclinical: in mouse models, trazodone improved memory measures and reduced signs of neurodegeneration [9]. In one experiment, a screen of 1,040 drugs identified trazodone and dibenzoylmethane as compounds that reversed eIF2-alpha phosphorylation-mediated translational repression in vitro and in vivo [9]. In mouse models of prion disease, trazodone restored memory deficits, prevented neurodegeneration and prolonged survival; in tauopathy-frontotemporal dementia mice it was neuroprotective, rescued memory deficits and reduced hippocampal atrophy, and trazodone also reduced p-tau burden [9]. The researchers concluded that trazodone, a licensed drug, should now be tested in clinical trials in patients [9]. Whether any of this happens in people taking trazodone for depression or for sleep is not established by these mouse experiments.

When confusion is a warning sign

Grogginess is not the only cause of confusion on this drug. The label lists mental status changes, including agitation, hallucinations, delirium and coma, among the signs of serotonin syndrome, which it says can occur with trazodone alone and becomes more likely with other serotonergic drugs such as triptans, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone and St John's wort [1]. The label says trazodone and any concomitant serotonergic agents are discontinued immediately if those symptoms occur, with supportive treatment started, and it contraindicates monoamine oxidase inhibitors, including linezolid and intravenous methylene blue, and their use within the previous 14 days [1].

Bottom line

What is known: the label warns of impaired judgment, thinking and motor skills and advises caution with machinery, and controlled trials recorded drowsiness, dizziness and blurred vision far more often than reported problems with concentration [1]. Measured performance effects appeared when trazodone levels were pushed up by low-dose ritonavir, a strong CYP3A4 inhibitor, and half-life is longer in older men and obese people [3][6]. What is not answered by these data is whether months or years of use change cognition; the human data here are adverse-reaction counts from controlled trials and small pharmacology and sleep studies [1][4].